High-dose N-acetylcysteine in patients with exacerbations of chronic obstructive pulmonary disease.

Abstract:

OBJECTIVE:To investigate the efficacy and tolerability of high-dose N-acetylcysteine (NAC) in the treatment of patients with exacerbations of chronic obstructive pulmonary disease (COPD). DESIGN AND PATIENTS:Randomised, double-blind, double-dummy, placebo-controlled study in 123 patients experiencing an acute exacerbation of COPD. INTERVENTIONS:NAC 1200 mg/day, 600 mg/day or placebo administered once daily for 10 days. MAIN OUTCOME MEASURES:The primary objective was to assess the proportion of patients with normalised C-reactive protein (CRP) levels. Also assessed were effects on interleukin (IL)-8 levels, lung function and symptoms. RESULTS:Both NAC 600 and 1200 mg/day were associated with a significantly higher proportion of patients achieving normalised CRP levels compared with placebo (52% and 90% vs 19% of patients; p

journal_name

Clin Drug Investig

authors

Zuin R,Palamidese A,Negrin R,Catozzo L,Scarda A,Balbinot M

doi

10.2165/00044011-200525060-00005

subject

Has Abstract

pub_date

2005-01-01 00:00:00

pages

401-8

issue

6

eissn

1173-2563

issn

1179-1918

pii

2565

journal_volume

25

pub_type

杂志文章